US20230372229A1 - Producing a topical solution composition - Google Patents
Producing a topical solution composition Download PDFInfo
- Publication number
- US20230372229A1 US20230372229A1 US18/305,935 US202318305935A US2023372229A1 US 20230372229 A1 US20230372229 A1 US 20230372229A1 US 202318305935 A US202318305935 A US 202318305935A US 2023372229 A1 US2023372229 A1 US 2023372229A1
- Authority
- US
- United States
- Prior art keywords
- solution composition
- topical solution
- extract
- topical
- red wine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 111
- 229940100613 topical solution Drugs 0.000 title claims abstract description 107
- 235000020095 red wine Nutrition 0.000 claims abstract description 49
- 230000003902 lesion Effects 0.000 claims abstract description 43
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 32
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 28
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 28
- 229940016667 resveratrol Drugs 0.000 claims abstract description 28
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 35
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 23
- 229920002125 Sokalan® Polymers 0.000 claims description 23
- 229960001631 carbomer Drugs 0.000 claims description 23
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims description 20
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 20
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 20
- 241000219094 Vitaceae Species 0.000 claims description 17
- 229930003427 Vitamin E Natural products 0.000 claims description 17
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 17
- 235000021021 grapes Nutrition 0.000 claims description 17
- 229940046009 vitamin E Drugs 0.000 claims description 17
- 235000019165 vitamin E Nutrition 0.000 claims description 17
- 239000011709 vitamin E Substances 0.000 claims description 17
- 229940088594 vitamin Drugs 0.000 claims description 15
- 229930003231 vitamin Natural products 0.000 claims description 15
- 235000013343 vitamin Nutrition 0.000 claims description 15
- 239000011782 vitamin Substances 0.000 claims description 15
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 14
- 229930003571 Vitamin B5 Natural products 0.000 claims description 14
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 14
- 229960002079 calcium pantothenate Drugs 0.000 claims description 14
- 235000009492 vitamin B5 Nutrition 0.000 claims description 14
- 239000011675 vitamin B5 Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 12
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 12
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 12
- XPFCZYUVICHKDS-UHFFFAOYSA-N 3-methylbutane-1,3-diol Chemical compound CC(C)(O)CCO XPFCZYUVICHKDS-UHFFFAOYSA-N 0.000 claims description 11
- 229940042585 tocopherol acetate Drugs 0.000 claims description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- 229940067596 butylparaben Drugs 0.000 claims description 10
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 10
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 10
- 229960002216 methylparaben Drugs 0.000 claims description 10
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 10
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 10
- 229960003415 propylparaben Drugs 0.000 claims description 10
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 10
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 9
- 240000000513 Santalum album Species 0.000 claims description 9
- 229960005323 phenoxyethanol Drugs 0.000 claims description 9
- 235000008632 Santalum album Nutrition 0.000 claims description 8
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 239000000230 xanthan gum Substances 0.000 claims description 8
- 229940082509 xanthan gum Drugs 0.000 claims description 8
- 235000010493 xanthan gum Nutrition 0.000 claims description 8
- 229920001285 xanthan gum Polymers 0.000 claims description 8
- 240000005979 Hordeum vulgare Species 0.000 claims description 7
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 7
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 7
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 7
- 229940101267 panthenol Drugs 0.000 claims description 7
- 235000020957 pantothenol Nutrition 0.000 claims description 7
- 239000011619 pantothenol Substances 0.000 claims description 7
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 7
- 235000018102 proteins Nutrition 0.000 claims description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 235000013871 bee wax Nutrition 0.000 claims description 6
- 229940092738 beeswax Drugs 0.000 claims description 6
- 239000012166 beeswax Substances 0.000 claims description 6
- 229960000541 cetyl alcohol Drugs 0.000 claims description 6
- 239000003995 emulsifying agent Substances 0.000 claims description 6
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 6
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 6
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 6
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 6
- 241001116389 Aloe Species 0.000 claims description 5
- 240000008067 Cucumis sativus Species 0.000 claims description 5
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 claims description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 5
- 235000004866 D-panthenol Nutrition 0.000 claims description 5
- 239000011703 D-panthenol Substances 0.000 claims description 5
- 241000195955 Equisetum hyemale Species 0.000 claims description 5
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims description 5
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 claims description 5
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 5
- 241000209140 Triticum Species 0.000 claims description 5
- 235000021307 Triticum Nutrition 0.000 claims description 5
- 235000009108 Urtica dioica Nutrition 0.000 claims description 5
- 229930003268 Vitamin C Natural products 0.000 claims description 5
- 235000011399 aloe vera Nutrition 0.000 claims description 5
- 235000020221 chamomile extract Nutrition 0.000 claims description 5
- 229940119217 chamomile extract Drugs 0.000 claims description 5
- 229940069826 chlorella vulgaris extract Drugs 0.000 claims description 5
- 229960003949 dexpanthenol Drugs 0.000 claims description 5
- 229940008099 dimethicone Drugs 0.000 claims description 5
- 229930182470 glycoside Natural products 0.000 claims description 5
- 150000002338 glycosides Chemical class 0.000 claims description 5
- 229940119170 jojoba wax Drugs 0.000 claims description 5
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 5
- 229940068041 phytic acid Drugs 0.000 claims description 5
- 235000002949 phytic acid Nutrition 0.000 claims description 5
- 239000000467 phytic acid Substances 0.000 claims description 5
- 229940032094 squalane Drugs 0.000 claims description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 5
- 235000019154 vitamin C Nutrition 0.000 claims description 5
- 239000011718 vitamin C Substances 0.000 claims description 5
- 239000010497 wheat germ oil Substances 0.000 claims description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- LUKBXSAWLPMMSZ-UPHRSURJSA-N Cis-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C/C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-UPHRSURJSA-N 0.000 claims description 4
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 4
- 240000006365 Vitis vinifera Species 0.000 claims description 4
- OEWBEINAQKIQLZ-CMRBMDBWSA-N [(2s)-2-[(2r)-3,4-bis(2-hexyldecanoyloxy)-5-oxo-2h-furan-2-yl]-2-(2-hexyldecanoyloxy)ethyl] 2-hexyldecanoate Chemical compound CCCCCCCCC(CCCCCC)C(=O)OC[C@H](OC(=O)C(CCCCCC)CCCCCCCC)[C@H]1OC(=O)C(OC(=O)C(CCCCCC)CCCCCCCC)=C1OC(=O)C(CCCCCC)CCCCCCCC OEWBEINAQKIQLZ-CMRBMDBWSA-N 0.000 claims description 4
- 229960001948 caffeine Drugs 0.000 claims description 4
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 4
- 229940059958 centella asiatica extract Drugs 0.000 claims description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 229940119168 tetrahexyldecyl ascorbate Drugs 0.000 claims description 4
- 235000018991 trans-resveratrol Nutrition 0.000 claims description 4
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims description 3
- 241001135917 Vitellaria paradoxa Species 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229930182478 glucoside Natural products 0.000 claims description 3
- 150000008131 glucosides Chemical class 0.000 claims description 3
- 229940057910 shea butter Drugs 0.000 claims description 3
- 229940042129 topical gel Drugs 0.000 claims description 3
- 229960004418 trolamine Drugs 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- 229940100611 topical cream Drugs 0.000 claims 2
- 244000274883 Urtica dioica Species 0.000 claims 1
- 229940082940 phellodendron amurense bark extract Drugs 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 56
- 238000000034 method Methods 0.000 description 33
- 239000000499 gel Substances 0.000 description 32
- 229940038487 grape extract Drugs 0.000 description 23
- 230000008569 process Effects 0.000 description 22
- 208000009621 actinic keratosis Diseases 0.000 description 20
- 239000004615 ingredient Substances 0.000 description 19
- 208000000069 hyperpigmentation Diseases 0.000 description 17
- 230000003810 hyperpigmentation Effects 0.000 description 17
- 238000000855 fermentation Methods 0.000 description 15
- 230000004151 fermentation Effects 0.000 description 15
- 239000006071 cream Substances 0.000 description 14
- 238000002156 mixing Methods 0.000 description 13
- 238000006722 reduction reaction Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 10
- 208000012641 Pigmentation disease Diseases 0.000 description 10
- 230000019612 pigmentation Effects 0.000 description 10
- 239000003963 antioxidant agent Substances 0.000 description 9
- 230000003078 antioxidant effect Effects 0.000 description 9
- 235000006708 antioxidants Nutrition 0.000 description 9
- HSTZMXCBWJGKHG-UHFFFAOYSA-N (E)-piceid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(C=CC=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-UHFFFAOYSA-N 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 150000008442 polyphenolic compounds Chemical class 0.000 description 8
- 235000013824 polyphenols Nutrition 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 239000008367 deionised water Substances 0.000 description 7
- 229910021641 deionized water Inorganic materials 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 229940084057 wine grape extract Drugs 0.000 description 7
- 239000006210 lotion Substances 0.000 description 6
- 241000219422 Urtica Species 0.000 description 5
- 229930003270 Vitamin B Natural products 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 235000019156 vitamin B Nutrition 0.000 description 5
- 239000011720 vitamin B Substances 0.000 description 5
- 206010036229 Post inflammatory pigmentation change Diseases 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- HSTZMXCBWJGKHG-BUFXCDORSA-N cis-piceid Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(\C=C/C=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-BUFXCDORSA-N 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- HSTZMXCBWJGKHG-CUYWLFDKSA-N trans-piceid Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-CUYWLFDKSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000033616 DNA repair Effects 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000000254 damaging effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 150000001629 stilbenes Chemical class 0.000 description 2
- 235000021286 stilbenes Nutrition 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- DMZOKBALNZWDKI-MATMFAIHSA-N trans-4-coumaroyl-CoA Chemical compound O=C([C@H](O)C(C)(COP(O)(=O)OP(O)(=O)OC[C@@H]1[C@H]([C@@H](O)[C@@H](O1)N1C2=NC=NC(N)=C2N=C1)OP(O)(O)=O)C)NCCC(=O)NCCSC(=O)\C=C\C1=CC=C(O)C=C1 DMZOKBALNZWDKI-MATMFAIHSA-N 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 235000014101 wine Nutrition 0.000 description 2
- OKDRUMBNXIYUEO-VHJVCUAWSA-N (2s,3s)-3-hydroxy-2-[(e)-prop-1-enyl]-2,3-dihydropyran-6-one Chemical compound C\C=C\[C@@H]1OC(=O)C=C[C@@H]1O OKDRUMBNXIYUEO-VHJVCUAWSA-N 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- 206010068388 Actinic elastosis Diseases 0.000 description 1
- 241000167550 Centella Species 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 241000972673 Phellodendron amurense Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- 101710199886 Protein 0.5 Proteins 0.000 description 1
- 244000044822 Simmondsia californica Species 0.000 description 1
- 235000004433 Simmondsia californica Nutrition 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- -1 Tetrahexyldecyl Chemical group 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000036569 collagen breakdown Effects 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 108010060641 flavanone synthetase Proteins 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000001329 hyperkeratotic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108010081296 resveratrol synthase Proteins 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229940100617 topical lotion Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Definitions
- the process for developing the topical solution is referenced in the flow chart within FIG. 3 which starts with the harvesting stage ( 10 ) where grapes are harvested for their rich magenta color.
- the grapes are then subjected to a fermentation process named in FIG. 3 as the fermentation stage ( 20 ) which is a process in which an agent causes an organic substance to break down into simpler substances.
- the fermentation process used to produce the grape extract in the present invention includes the addition of yeast as the agent which causes the anaerobic breakdown of the sugar within the grape extract into alcohol. It is important that the fermentation parameters are strictly enforced. Too much fermentation yields an alcohol level that is more than two percent by volume.
- topical solution composition gel examples include ingredients, including but not limited to: deionized water, red wine extract, Aloe barbendesis leaf juice, cucumber extract, hyaluronic acid, isoprene glycol, tocopherol acetate (Vitamin E), chamomile extract, jojoba oil, hydrolized silk protein, nettle extract, hydrolyzed wheat protein, phytic acid, wheat germ oil, horsetail extract, Centella asiatica extract, Chlorella vulgaris extract, hydrolized align, butylene glycol, D-Panthenol (Vitamin B5), caffeine extract, carbomer, phenoxyethanol, methylparaben, butylparaben, ethylparaben, propylparaben, triethanolamine, or combinations thereof.
- ingredients including but not limited to: deionized water, red wine extract, Aloe barbendesis leaf juice, cucumber extract, hyaluronic acid, isoprene glycol, tocopherol a
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Cosmetics (AREA)
Abstract
Description
- This present application is a Continuation Application of U.S. application Ser. No. 16/997,121, filed on Aug. 19, 2020 (now allowed), which is a Continuation Application of U.S. application Ser. No. 15/715,037, filed on Sep. 25, 2017 (now U.S. Pat. No. 10,888,515), which is a Continuation-in-Part of U.S. application Ser. No. 15/685,687, filed on Aug. 24, 2017 (abandoned), which is a Continuation Application of U.S. application Ser. No. 11/837,735, filed on Aug. 13, 2007 (now U.S. Pat. No. 9,770,480), the entirety of which is incorporated herein by reference and made a part of the present disclosure.
- The present invention is generally related to a topical solution composition that revitalizes layers of the skin.
- The primary objective of the present invention is to produce a skin topical solution composition that revitalizes damaged skin. The production of the topical solution is accomplished by providing a grape extract and adding vitamins that are capable of increasing the pH and an aqueous solution with a carbomer base where the carbomer base acts as an emulsion stabilizer and where the grape extract is subjected to a fermentation and mixing process that yields the highest conversion of cis- and trans-piceid (a glucoside-analog of resveratrol) into cis- and trans-resveratrol.
- The topical solution comprises a number of ingredients depending on if the desired final form of the topical solution is a gel or a cream. At a minimum the ingredients for the topical solution must include a grape extract, vitamins that are capable of increasing the pH and an aqueous solution with a carbomer base where the carbomer acts as an emulsion stabilizer and where the grape extract is subjected to a fermentation and mixing process that yields the highest conversion of cis- and trans-piceid (a glucoside-analog of resveratrol) into cis- and trans-resveratrol.
-
FIG. 1 Image of subject before and after using the skin lotion. -
FIG. 2 Image of subject before and after using the skin lotion. -
FIG. 3 is a simplified process flow diagram for developing a topical solution. -
FIG. 4A is a photograph of the face of patient #1 on day 1 of the experiment described in Example 1, prior to any application of the topical solution composition, where lesions are visibly apparent on patient #1. -
FIG. 4B is a photograph of the face of patient #1 onday 30 of the experiment described in Example 1, after the final application of the topical solution composition, where the number and/or size of the lesions that are visibly apparent on patient #1 have been reduced relative toFIG. 4A . -
FIG. 5A is a photograph of the face of patient #2 on day 1 of the experiment described in Example 1, prior to any application of the topical solution composition, where lesions are visibly apparent on patient #2. -
FIG. 5B is a photograph of the face of patient #2 onday 30 of the experiment described in Example 1, after the final application of the topical solution composition, where the number and/or size of the lesions that are visibly apparent on patient #2 have been reduced relative toFIG. 5A . - The present invention relates to revitalizing layers of the skin which have been damaged by the environment. More specifically, sunlight exposure and particularly ultraviolet radiation can cause a variety of skin changes and damages such as premature aging, and skin cancer. There are three main types of UV radiation, UVA, UVB, and UVC. UVC has the shortest wavelength. UVA on the other hand has the longest wavelength. However, as with any electromagnetic energy, the shortest wavelength is the most susceptible to obstruction while the longest wavelength is the least. UVC for example is almost completely blocked by the ozone layer in our atmosphere, while UVB penetrates the atmosphere relatively unobstructed and causes damage in the outer layer of the skin. UVB, however, does not penetrate glass. UVA, on the other hand, can penetrate glass and deeper into the skin to cause skin damage.
- On a cellular level, UV radiation can cause collagen breakdown, creation of free radicals, interfere with DNA repair, and suppress the immune system's ability to survey and destroy cancerous cells. Of these damaging effects, perhaps the most significant is the creation of free radicals.
- Oxygen molecules normally exist in stably bonded pairs. Free radicals are created when ionizing energy like UV radiation strikes a stable, paired oxygen molecule splitting its paired electron bonding, resulting in two single oxygen molecules. These two oxygen molecules each have one unpaired valence electron that is very reactive inside human tissues and cells. These free radical oxygen molecules react with organic molecules in the connective tissue and cells stealing electrons away from structures that require those electrons for stable bonds. This causes damage to enzymes, DNA's, collagen structures and cell wall stability and permeability. Damage to these cellular structures can cause for example. DNA mutations (that lead to cancerous behavior); suppression of enzymatic functions that regulate cellular signaling, apoptosis, immune functions, as well as, DNA repair.
- One well known skin condition that occurs as a result of prolonged, cumulative effect of sun exposure is Actinic Keratosis, (AK's). AK's are by far the most common skin lesion with malignant potential on the skin. These lesions develop in a stepwise progression from subclinical skin changes to overt, invasive Squamous Cell Carcinoma, (SCC). If left untreated, these AK lesions have 1 per 1000 per year chance of becoming cancerous.
- Clinically, AK's present with a range of characteristics. They can be barely perceptible to rough, elevated hyperkeratotic plagues several centimeters in diameter. The base may be light or dark, tan, pink, red, or a combination of these. Most typically though, they appear as multiple discrete lesions that are small crusty, scaly or crumbly bump or horn on an erythematous base.
- Histologically, AK's share features with SCC. The histological characteristics are as follows: AK's are located in the epidermis and show hyperkeratosis with intermittent large parakeratotic nuclei and occasional mitotic figures; keratinocyte atypia along the basal layer spongiosis in the immediate suprabasalar layer; budding of the basal layer keratinocytes into the dermis; perivascular inflammation and solar elastosis.
- Treatment of AK's typically consists of surgical destruction. The difficulty with surgical destruction is that it is difficult and impractical to treat a large area of the skin that has large number of lesions.
- Hyperpigmentation is the condition of the appearance of excessive pigmented lesions on skin, which are often considered unsightly and undesirable. The causes of hyperpigmentation can vary but include excessive exposure to UVA and UVB radiation, detrimental environmental stress on skin through extended exposure, the side effects of light-based medical therapies on skin via laser or other devices (which is known as PIH or “Post-Inflammatory Hyperpigmentation”), hormonal changes to the human body that occur during or after pregnancy, as well as conditions such as melasma where pigmentation is a known side effect, or other physiological changes to the human body that can exhibit hyperpigmentation as a reaction to stress or inability to process toxicity within the body.
- Historically hyperpigmentation has been one of the most difficult skin conditions to treat cosmetically, with traditional methods focusing on physical reduction of the pigment at the outermost layer of the skin (the stratum corneum) via a manual or chemical exfoliation process. The application of hydroquinone, a synthetic chemical originally compounded as a means of developing photographs, as a topically-applied medicine to reduce hyperpigmentation became a widely used method since the 1970s. However, hydroquinone has been found to have potentially significant effects if applied for too long of a period of time or if applied in higher concentrations. Specifically, there have been many documented cases of ocrhnosis where hyperpigmention is known to appear as a reaction to high does of hydroquinone and becomes intractable within skin. Because of safety considerations the health agencies of many nations have severely restricted or banned hydroquinone from use altogether, or at a minimum eliminated it as an OTC or “over the counter” medicine.
- As a result, there is a need for a safer yet still effective means of reducing hyperpigmention through topical means. There have been several alternative compounds, both synthetic and from a botanical source, that have been applied to reduce hyperpigmentation, such as Vitamin C or Kojic Acid. However, these methods often have drawbacks in terms of difficulty to chemically stabilize, and have undesirable side effects on skin when applied.
- The use of the present invention which, was further proven in studies performed by an independent research investigator at the Palo Alto Medical Foundation, greatly improves or completely resolves AK lesions. Furthermore, since the present invention consists of a topical solution that is topically applied it is not limited to impracticalities of treating large areas of the skin like surgical destruction.
- Recently there has been significant interest in the medical and health industry generated about red wine. Red wine is known to have several biologically active compounds; most of them belong to a family known as polyphenols. Polyphenols are of great interest to the medical and health industry because of the potential benefits to human health. These compounds possess antioxidant, anti-inflammatory, and anticarcinogenic properties that are the focus of many current research investigations.
- Polyphenols are a group of heterogeneous compounds with four main classes: flavonols, stilbenes, flavones, and phenolic acids. Such compounds include, for example, proanthocyanidins, quercitin, anthocyanins, and resveratrol and its glucoside analogs). Studies involving these four main classes suggest that of the polyphenols, resveratrol may the most effective in anticancer property.
- Resveratrol exist as a cis-isomer and a trans-isomer. It falls under a class of polyphenols known as stilbenes. A glucoside analog of resveratrol is found naturally, to varying levels, in the skin of grapes in its isomeric forms called cis- and trans-piceid.
- In the past, it was not known how to produce a grape extract to include in a topical solution where the grape extract was not damaged in the production process. Also, it was not known how to produce a grape extract that yields high levels of resveratrol. Finally due to fact that red wine and red wine's extract naturally has an extremely low pH (between 1.0 and 2.0) it was not known how to produce a topical solution that would not inflame or burn the skin.
- In the present invention the grape extract is mixed by using a cold process which does not damage the grape extract, parameters in the fermentation process are heavily controlled to maintain a specific rage that yields high levels of resveratrol and certain ingredients are used in the production process that increases the natural pH level of red wine thereby allowing one to produce a topical solution with an acceptable pH and with the highest quantity of active polyphenols.
- The topical solution composition of the present invention includes a grape extract which is produced predominantly from grapes that are rich in magenta color. We have found that grapes that are rich in magenta color yield the highest amount of resveratrol due to the high tannin content of the grapes' skin. We have also found that certain vintages like Merlot and Cabernet yield the highest form of resteratrol content because their vintage process includes more parts of the grapes' skin. Furthermore, there is a well known method of testing, growing and producing grapes with high levels of resveratrol.
- The process for developing the topical solution is referenced in the flow chart within
FIG. 3 which starts with the harvesting stage (10) where grapes are harvested for their rich magenta color. The grapes are then subjected to a fermentation process named inFIG. 3 as the fermentation stage (20) which is a process in which an agent causes an organic substance to break down into simpler substances. The fermentation process used to produce the grape extract in the present invention includes the addition of yeast as the agent which causes the anaerobic breakdown of the sugar within the grape extract into alcohol. It is important that the fermentation parameters are strictly enforced. Too much fermentation yields an alcohol level that is more than two percent by volume. The increased level of alcohol above two percent by volume is a result that occurs when the fermentation process has begun to break down the Coumaroyl CoA molecule thereby not allowing it to yield the best reaction thereby yielding a long chain molecule. The preferred length of fermentation for the present invention depends on the temperature and humidity and the preferred range is between seven days at a temperature of ninety five degrees Fahrenheit and 80 percent humidity to forty five at a temperature of thirty five degrees Fahrenheit and 30 percent humidity. This range yields the highest conversion of cis- and trans-piceid (a glucoside-analog of resveratrol) into cis-and trans-resveratrol without oxidizing the polyphenols. After the fermentation process the grapes are then subjected to an extraction process which is performed in the extraction stage (30), where the water and ethanol content produced during the fermentation process is slowly removed leaving only the constituents of the grapes behind in a stable powder form. - This powder form of the grape extract is then subjected to the mixing stage (40) where depending if the designed outcome of the topical solution is a gel or cream various ingredients are added. The mixing process is particularly inventive due to the cold process mixing methods employed to mix the powder form of the grape extract into an aqueous solution with a carbomer base. Additional ingredients are then further added and mixed to increase the level of pH. The traditional mixing process uses heat to melt the ingredients thereby allowing the ingredients to adequately mix together. It is well known in the art of producing skin lotions to use high temperatures between 100 and 300 degrees Celsius in order to facilitate the melting and mixing of the ingredients. We have found that the use of high temperatures causes heat-oxidation in the grape extract. Heat oxidation occurs when elevated temperatures increase the activity of oxygen and serves as a catalyst by exothermic reactions for the formation of Radical Oxygen Species (ROS) from oxygen. When anti-oxidants such as resveratrol are exposed to heat-oxidation they bind with the ROS thereby decreasing the amount of resveratrol. In effect, heat-oxidization prematurely reduces or eliminates the anti-oxidant benefits of the grape extract.
- In the present invention the mixing process of the grape extract is performed in room temperature between twenty to forty degrees Celsius thereby reducing any oxidation of the polyphenols caused by heat. This low temperature mixing process uses ingredients that are capable of being mixed without the need for increased temperatures.
- This limits the types of ingredients one can use to in a skin lotion. We found that the following ingredients and their percentages are most contusive to mixing by use of a cold process when producing a topical solution using the present invention where the topical solution is in the form of a gel:
-
Gel Ingredients: Percentage D.I. Water 68.10 RedWine Extract 5.00 Aloe Barbensis Extract 4.00 Cucumber Extract 3.00 Hylauronie Acid 2.50 Isoplene Glycol 2.00 Tocopherol Acetate 2.00 Chamomile Extract 2.00 Jojoba Oil 2.00 Hydrolyzed Milk Protein 2.00 Nettle (Urtica Diolica) Extract 0.50 Hydrolyzed Wheat Protein 0.50 Phytic Acid 0.50 Wheat Germ Oil 0.50 Horsetail Extract 0.50 Centella Assistica Extract 0.50 Chlorella Vulgaris Extract 0.50 Hydrolyzed Algin 0.50 Butylene Glycol 0.50 Naicinamide 0.50 Adensosine Triphosphate 0.50 D-Panthenol (Vitamin B5) 0.50 Carbomer 0.20 Xanthan Gum 0.20 Methylparaben 0.20 Butylparaben 0.20 Ethylparaben 0.20 Propylparaben 0.20 Triethanolamine 0.20 100.00 - We also found that the following ingredients are most contusive to mixing by use of a cold process when producing a topical solution using the present invention where the topical solution is in the form of a cream:
-
Cream Deionized Water 62.6.0 Grape extract 6.00 Isoprene Glycol 5.00 Squalane 4.00 Santalum Album Sandalwood Extract 4.00 Phellodendron Amurense Bank Extract, Hordeum Distichon (Barley) Extract, Polyglyceryl-2 Stearate 2.00 Ceteary Methicone (and) Dimethicone 2.00 (and) Linleic Acid (and) Glycine Soja (soybean) Sterol (and) Phosopholipids Dimethylopolsiloxane 2.00 Chenesis (Jojoba) Seed Oil 2.00 Tetrahexyldecyl Ascrobate 3.00 Tocopheryl Acetate (Vitamin E) 3.00 Cetyl Alcohol 1.00 Shea Butter 1.00 Phenoxyethanol (and) Methylparaben 1.00 (and) Butylparaben (and) Ethylparaben (and) Propylparaben Bees Wax 0.50 Cetearyl Glycoside 0.50 Xanthan Gum 0.20 Carbomer 0.2 Total 100.00 - It is important a topical lotion have a pH no less than 2.5 and no more than 8.0. If the pH of the topical solution composition is less than a pH of 2.5 or more than a pH of 8.0 the topical solution will burn the skin. The pH level of grape extract is between 1.0 and 2.0 which if applied would burn the skin. Therefore additional materials must be added to increase the pH level. In the present invention a form of vitamin E for example Tocopherol with a pH level between 4.0 and 7.0 is added to the topical solution and a form of vitamin B for example Panthenol with a pH level between 4.0 and 7.0 is added to the topical solution to increase the pH level. Either a form of vitamin E, a form of vitamin B or a form of vitamin E and vitamin B may be used to increase the level of pH of the grape extract. Furthermore it is well known in the art that both vitamin E and vitamin B act to moisturize the skin thereby further complimenting the topical solution. Also, vitamin E and vitamin B are compatible with the cold process of the present invention.
- The topical solution composition comprises: 0.1% to 50.0% of Grape extract of the total mixture and 0.100% to 50.0% of an aqueous solution with a carbomer base of the total mixture, 0. 1% to 50.0% of Vitamin B5, 0. 1% to 50.0% of Vitamin E and, 0.1% to 50.0% water of the total mixture.
- Results of our clinical study where subjects used the topical solution showed statistically significant improvements in AK's on skin. Each study subject was his/her own control. One side of the face was treated with the topical solution, while the other side was treated with a placebo gel which was simply the vehicle of the first topical gel without the skin lotion. The results show approximately 50%-85% improvement of AK's on the treatment side while the placebo side show little improvement or even progression of AK's. For example, in
FIG. 1 , the subject's treated side prior to treatment show 5 AK lesions and post-treatment show only 3 AK's. InFIG. 2 , the treatment side of this subject showed 5 AK lesions and post-treatment shows only 1 AK lesion. These results were based on gross visual exam by the research investigator whose specialty is dermatology and confirmed by biopsy of skin lesions of the subjects on both sides of their faces. - The reduction of AK lesions after treatment with the skin lotion effectively makes it possible to treat a large area of skin affected with large number of AK's without significant side effects or discontinuation due to discomfort. Also, because our product has a low side effect profile, it can be used as a long-tern maintenance product for patients with sun damaged skin to treat any subclinical cellular atypia that may not have been detected yet.
- During the fermentation process resveratrol is produced from a Courraroyl CoA molecule with three Coumaroyl CoA molecules in three successive reduction reactions yielding a long chain molecule called tetraketide with a single benzene ring. Then that molecule is further process in acyclization process by either the resveratrol synthase or chalcone synthase to yield the final product of resveratrol or quercitin respectively. Our experience with various forms of red wine from a variety of grapes, and length of fermentation has resulted in a product that contains the highest quality of grape extract.
- Various embodiments of the invention have been described. These and other embodiments are within the scope of the following claims.
- Certain aspects of the present disclosure include a red wine based composition suitable for use in the inhibition of pigmented lesions on human skin, to methods of making such a composition, and the methods of use of such a composition. Some such aspect includes a topical solution composition that exhibits the ability to lighten the appearance of human skin.
- Without being bound by theory, it is believed that resveratrol, functioning as an anti-oxidant, has the effect of reducing melanin deposits on the surface of human skin. Resveratrol, a compound within red wine grape extract, has significant anti-inflammatory and anti-oxidant abilities. As the sole active ingredient, however, resveratrol is typically not directly applied to skin except in very small quantities, because resveratrol can cause skin irritation.
- Without being bound by theory, it is believed that red wine grape extract, having a high concentration of resveratrol, has significant benefits for anti-oxidant activity upon human skin. For example, as disclosed in U.S. patent application Ser. No. 11/837,735 (the '735 application) and U.S. patent application Ser. No. 15/685,687 (the '687 application), grapes, fermented in accordance with the fermentation procedures described therein to develop the strength of the resveratrol without damaging its antioxidant abilities, are combined with vitamins in a carbomer base to create an effective topical composition to restore UV-radiation damaged skin. The abilities of such formulations were established by testing such formulations on patients with Actinic Keratosis (AK), a precursor condition to Squamous Cell Carcinoma (SCC) where lesions are visible on affected skin. The red wine-based topical solutions of such formulations exhibited the ability to reduce the appearance of AKs by an average of at least 75 percent within a two-month period of application. However, without being bound by theory, application of such formulations of red wine grape extract upon skin within a carbomer-based emulsifier does not appear to affect hyperpigmentation in a significant way, despite the relatively high anti-oxidant strength of such formulations. Still, without being bound by theory, it is believed that red wine extract does have the potential to be effective versus hyperpigmentation and especially PIH (post-inflammatory hyperpigmentation) because of red wine's anti-inflammatory properties.
- In some aspects, the topical solution composition exhibits the ability to reduce the appearance of excessive pigmentation, or “hyperpigmentation”, and to lighten the appearance of human skin. The production of the topical solution is accomplished by providing a grape wine extract (also referred to herein as a grape extract) and adding vitamins that are capable of altering the pH of the topical solution composition within an aqueous solution with a carbomer base. The carbomer base acts as an emulsion stabilizer or “emulsifier.”
- In some aspects, the use of the topical solution composition disclosed herein reduces the appearance of hyperpigmentation by combining the extract of red wine grapes with one or more vitamins that function adjust the pH of the topical solution composition to an ideal level for maximum effect, without causing inflammation to the user's skin upon application.
- Certain aspects of the present disclosure include a base formula of extract using a high concentration of magenta-colored red wine grapes that are fermented into wine via a controlled process, as specified herein above and in the ‘735 and 687’ applications. Such extract of such fermented grapes is then combined with one or more vitamins, such as Panthenol (Vitamin B5) and/or Tocopherol Acetate (Vitamin E). In some such aspects, the vitamins are combined with the extract within a cold manufacturing process, in which the extract and vitamins are mixed at a temperature of ranging between 20 degrees Celsius and 40 degrees Celsius to compound a stable solution that maximizes the effects of a high concentration of resveratrol within the red wine extract. Panthenol and Tocopherol Acetate are used within the solution to adjust the pH level in order to maintain the solution's anti-oxidant effectiveness and stability.
- In certain aspects, the pH of the topical solution composition ranges from 2.5 to 5.5, or from 3.0 to 5.0, or from 3.5 to 4.5, for example. As evidenced below, in Example 1, it has been found that when the pH of the topical solution composition is from 2.5 to 5.5, the topical solution composition is effective in reducing the visibility of pigmented lesions on skin without causing skin irritation. In some such aspects, the topical solution composition has a pH of from 2.5 to 5.5 and a content of red wine grape extract of from 1.0 to 50.0 weight percent. Without being bound by theory, it is believed that an otherwise identical topical solution composition having a pH of greater than 5.5 is not effective at reducing the visibility of pigmented lesions on skin without causing skin irritation, and that an otherwise identical topical solution composition having a pH of less than 2.5 causes skin irritation.
- In some aspects, a topical solution composition in accordance with the present disclosure, having a pH of from 2.5 to 5.5 and a content of red wine grape extract of from 1.0 to 50.0 weight percent, is capable of reducing the number of visible lesions by from 10% to 50%, or from 15% to 40%, or from 20% to 35%, or from 25% to 30% (e.g., after a twice daily application of the topical solution composition onto the skin over a thirty-day period). For example, if a user applies the topical solution composition to an affected area having ten visible lesions, twice daily for thirty days, that user may experience a reduction in the number of visible lesions by from 10% to 50% (i.e., reducing the number of visible lesions from an original 10 visible lesions to a resulting number of visible lesions ranging from 9 to 5). One skilled in the art would understand that the number of visible lesions reduced by use of the present topical solution composition is not limited to these percentages.
- Without being bound by theory, it is believed that the reduction of hyperpigmentation results from a combination of the anti-oxidant and anti-inflammatory properties of red wine grape extract and the composition having a pH ranging from 2.5 to 5.5. Healthy and normal human skin has a pH of approximately 7.0 or neutral pH. However, the outer layers of human skin within the stratum corneum and epidermal layer have a pH level of approximately 5.5 for normal, healthy skin. Thus, by having a pH adjusted to reside within the range of 2.5 to 5.5, the present composition is more effective in reducing lesions of pigmentation on the upper skin layers, as well as reducing visible inflammation. That the pH levels maintain a difference in performance is an observation unique to the present composition, as one skilled in the art would have no expectation of success in adjusting the pH level of a topical solution to enhance that solutions abilities to reduce hyperpigmentation. In fact, often solutions of known skin lighteners, such as hydroquinone, require functional pHs of 2.0 or lower to be deemed effective. Thus, the present composition surprisingly and unexpectedly exhibits skin lightening capability at a pH ranging from 2.5 to 5.5.
- The content of red wine grape extract may range from 1.0 to 50.0 weight percent, or from 5 to 45 weight percent, or from 10 to 40 weight percent, or from 15 to 35 weight percent, or from 20 to 30 weight percent, based on a total weight of the topical solution composition.
- The use of the cold manufacturing process described herein, the use of a pH range of from 2.5 to 5.5, and the need to stabilize the red wine extract within the emulsion are each considered when determining the types and amounts of additives and additional ingredients included within the topical solution composition.
- In some aspects, the topical solution composition is in the form of a gel. In other aspects, the topical solution composition is in the form of a cream.
- Some aspects of the topical solution composition gel include ingredients, including but not limited to: deionized water, red wine extract, Aloe barbendesis leaf juice, cucumber extract, hyaluronic acid, isoprene glycol, tocopherol acetate (Vitamin E), chamomile extract, jojoba oil, hydrolized silk protein, nettle extract, hydrolyzed wheat protein, phytic acid, wheat germ oil, horsetail extract, Centella asiatica extract, Chlorella vulgaris extract, hydrolized align, butylene glycol, D-Panthenol (Vitamin B5), caffeine extract, carbomer, phenoxyethanol, methylparaben, butylparaben, ethylparaben, propylparaben, triethanolamine, or combinations thereof. Some aspects of the topical solution composition gel include deionized water in an amount ranging from 51 to 95 weight percent, or from 60 to 90 weight percent, or from 65 to 85 weight percent, or 70.9 weight percent. Some aspects of the topical solution composition gel include red wine extract in an amount ranging from 1 to 50 weight percent, or from 2 to 20 weight percent, or from 3 to 10 weight percent, or 5 weight percent. Some aspects of the topical solution composition gel include Aloe barbendesis leaf juice in an amount ranging from 1 to 10 weight percent, or from 2 to 8 weight percent, or from 2.5 to 5 weight percent, or 3 weight percent. Some aspects of the topical solution composition gel include cucumber extract, hyaluronic acid, isoprene glycol, tocopherol acetate (Vitamin E), chamomile extract, jojoba oil, hydrolized silk protein, each, if present, in an amount ranging from 1 to 10 weight percent, or from 1.5 to 8 weight percent, or from 2 to 5 weight percent, or 2 weight percent. Some aspects of the topical solution composition gel include nettle extract, hydrolyzed wheat protein, phytic acid, wheat germ oil, horsetail extract, Centella asiatica extract, Chlorella vulgaris extract, hydrolized align, butylene glycol, D-Panthenol (Vitamin B5), caffeine extract, and carbomer, each, if present, in an amount ranging from 0.1 to 5 weight percent, or from 0.2 to 3 weight percent, or from 0.3 to 1 weight percent, or 0.5 weight percent. Some aspects of the topical solution composition gel include phenoxyethanol, methylparaben, butylparaben, ethylparaben, propylparaben, triethanolamine, each, if present, in an amount ranging from 0.01 to 1 weight percent, or from 0.02 to 0.5 weight percent, or from 0.09 to 0.3 weight percent, or 0.2 weight percent, or 0.1 weight percent. An exemplary gel composition, conducive to mixing via the cold manufacturing process when producing the topical solution composition, is set forth in the following Table, below.
-
TABLE Red Wine Gel for reducing hyperpigmentation Red Wine Gel for reducing hyperpigmentation Percentages Ingredients by volume Deionized Water 70.9 Red Wine Extract 5.0 Aloe Barbendesis Leaf Juice 3.0 Cucumber Extract 2.0 Hyaluronic Acid 2.0 Isoprene Glycol 2.0 Tocopherol Acetate (Vitamin E) 2.0 Chamomile Extract 2.0 Jojoba Oil 2.0 Hydrolized Silk Protein 2.0 Nettle Extract 0.5 Hydrolyzed Wheat Protein 0.5 Phytic Acid 0.5 Wheat Germ Oil 0.5 Horsetail Extract 0.5 Centella Asiatica Extract 0.5 Chlorella Vulgaris Extract 0.5 Hydrolized Algin 0.5 Butylene Glycol 0.5 D-Panthenol (Vitamin B5) 0.5 Caffeine Extract 0.5 Carbomer 0.5 Phenoxyethanol 0.2 Methylparaben 0.2 Butylparaben 0.2 Ethylparaben 0.2 Propylparaben 0.2 Triethanolamine 0.1 - Some aspects of the topical solution composition cream include ingredients, including but not limited to: deionized water, red wine extract, isoprene glycol, dimethicone, dimethylpolisiloxane, squalane, chinesis seed oil, tetrahexyldecyl ascorbate (Vitamin C), tocopherol acetate (Vitamin E), panthenol (Vitamin B5), cetyl alcohol, shea butter, bees wax, cetearyl glycoside, xanthan gum, carbomer, Santalum album (sandalwood) extract, Phellondendron amurence bark extract, Hordeium distichon (barley) extract, phenoxyethanol, methylparaben, propylparaben, butylparaben, or combinations thereof. Some aspects of the topical solution composition cream include deionized water in an amount ranging from 40 to 95 weight percent, or from 50 to 80 weight percent, or from 55 to 70 weight percent, or 60 weight percent. Some aspects of the topical solution composition cream include red wine extract in an amount ranging from 1 to 50 weight percent, or from 2 to 20 weight percent, or from 3 to 10 weight percent, or 6 weight percent. Some aspects of the topical solution composition cream include isoprene glycol, dimethicone, dimethylpolisiloxane, or combinations thereof, each, if present, in an amount ranging from 1 to 10 weight percent, or from 1.5 to 8 weight percent, or from 2 to 5 weight percent, or 4 weight percent or 5 weight percent. Some aspects of the topical solution composition cream include squalane, Chinese seed oil, tetrahexyldecyl ascorbate (Vitamin C), tocopherol acetate (Vitamin E), panthenol (Vitamin B5), cetyl alcohol, shea butter, bees wax, cetearyl glycoside, xanthan gum, or combinations thereof, each, if present, in an amount ranging from 0.1 to 10 weight percent, or from 0.2 to 8 weight percent, or from 0.3 to 5 weight percent, or from 1 to 2 weight percent, or 1 weight percent, or 2 weight percent. Some aspects of the topical solution composition cream include carbomer, Santalum album (sandalwood) extract, Phellondendron amurence bark extract, Hordeium distichon (barley) extract, phenoxyethanol, methylparaben, propylparaben, butylparaben, or combinations thereof, each, if present, in an amount ranging from 0.1 to 5 weight percent, or from 0.2 to 3 weight percent, or from 0.25 to 1 weight percent, or from 0.25 to 0.5 weight percent, or 0.5 weight percent, or 0.25 weight percent. An exemplary cream composition, conducive to mixing via the cold manufacturing process when producing the topical solution composition, is set forth in the following Table, below.
-
TABLE Red Wine Cream for reducing hyperpigmentation Red Wine Cream for reducing hyperpigmentation Percentages Ingredients by volume Deionized Water 60.0 Red Wine Extract 6.0 Isoprene Glycol 5.0 Dimethicone 4.0 Dimethylpolisiloxane 4.0 Squalane 2.0 Chinesis Seed Oil 2.0 Tetrahexyldecyl Ascorbate (Vitamin C) 2.0 Tocopherol Acetate (Vitamin E) 2.0 Panthenol (Vitamin B5) 2.0 Cetyl Alcohol 2.0 Shea Butter 2.0 Bees Wax 2.0 Cetearyl Glycoside 1.0 Xanthan Gum 1.0 Carbomer 0.5 Santalum Album (Sandalwood) Extract 0.5 Phellondendron Amurence Bark Extract 0.5 Hordeium Distichon (Barley) Extract 0.5 Phenoxyethanol 0.25 Methylparaben 0.25 Propylparaben 0.25 Butylparaben 0.25 - As is understood by those skilled in the art, different combinations of ingredients may be used without deviating from the scope of the present disclosure.
- A trial experiment was conducted to investigate a red wine gel formulation in accordance the formulation listed in the Table above (TABLE—Red Wine Gel for reducing hyperpigmentation).
- Unit A: Red wine & Vitamin B5 Gel at a 5 weight % concentration; with a pH of 5.5
- Unit B: Red Wine & B5 Gel at a 5 weight % concentration; with a pH at 2.5
- Unit C: Control gel consisting of Vitamin B5 but no red wine extract; with a pH at 7.0
- Six patients were included in the study:
- #1: 65 year old Asian female
- #2: 50 year old Asian female
- #3: 50 year old Asian female
- #4: 45 year old Caucasian male
- #5: 25 year old Hispanic male
- #6: 25 year old Asian male
- All subjects at the time of the testing were of generally good health.
- The subjects (i.e., six patients) were each given a 30 ml bottle of a gel formulation that was marked A, B or C, corresponding to Units A, B, and C. Thus, each bottle corresponded to one of the test materials. The subjects were instructed to wash their face and then apply the gel twice daily: once in the morning and once before going to sleep. The amount applied to the face was 0.3 grams per dose (per application). The study was conducted for 30 days.
- The study was judged based on the attained reduction of visible pigmentation lesions by area, by visual assessment from Day 1 of the study before the first application of gel, to the
Day 30 of the study, after the final application of gel. The results are presented in the Table below. -
TABLE Example 1 Study Results Subject Gel Used Result Day 1 Result Day 301 B — 50% reduction in visible pigmentation lesions 2 B — 45% reduction in visible pigmentation lesions 3 A — 10% reduction in visible pigmentation lesions 4 C — 0% reduction in visible pigmentation lesions 5 C — 3% reduction in visible pigmentation lesions 6 A — 18% reduction in visible pigmentation lesions - The percentage in the Table is the amount of area of pigmented lesions reduced on the face. This was done as a self-assessment by the subject, and also by an observer to determine the amount of reduced lesions.
- This study was able to observe that there was a noticeably visible result from application of gels with Red Wine Extract on reducing pigmented lesions, and that this result was especially apparent on gels with a lower pH than 7.0. Compared to the control gel, both of the red wine gels were able to display visible results.
- It was found however that when the pH of the gel was narrowed to between 2.5 and 5.5, and not exceeding 5.5, and when the concentrations of the red wine extract were between 1.0% and 50.0%, that the resulting gel was observed as being effective in reducing the visibility of pigmented lesions on skin that it was applied to. Topical solutions employing red wine extract that had a pH above 5.5 were found not to be effective in reducing hyperpigmented lesions on skin, while solutions that were below 2.5 were found to be highly inflammatory on skin to the point of ineffectiveness.
- It should be noted and understood that many of the specific features or combination of features illustrated in or introduced above (or described in the claims submitted below), and\or discussed in accompanying descriptions, may be combined with or incorporated with or other feature(s) described or illustrated in any other Figure provided herein. Moreover, the following claims serve also to describe and illustrate some (but not all) aspects of the present disclosure. The claims serve therefore as an integral part of the present disclosure.
- The foregoing description has been presented for purposes of illustration and description of preferred aspects. This description is not intended to limit associated concepts to the various compositions, processes, and methods specifically described herein. For example, aspects of the processes and compositions illustrated by the Figures and discussed above may be employed or prove suitable for use with methods and compositions. The aspects described and illustrated herein are further intended to explain the best modes for practicing the compositions and methods, and to enable others skilled in the art to utilize same and other aspects and with various modifications required by the particular applications or uses of the present disclosure.
Claims (21)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/305,935 US20230372229A1 (en) | 2007-08-13 | 2023-04-24 | Producing a topical solution composition |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/837,735 US9770480B2 (en) | 2007-08-13 | 2007-08-13 | Producing a topical solution coposition |
US201715685687A | 2017-08-24 | 2017-08-24 | |
US15/715,037 US10888515B2 (en) | 2007-08-13 | 2017-09-25 | Producing a topical solution composition |
US16/997,121 US11654099B2 (en) | 2007-08-13 | 2020-08-19 | Producing a topical solution composition |
US18/305,935 US20230372229A1 (en) | 2007-08-13 | 2023-04-24 | Producing a topical solution composition |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/997,121 Continuation US11654099B2 (en) | 2007-08-13 | 2020-08-19 | Producing a topical solution composition |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230372229A1 true US20230372229A1 (en) | 2023-11-23 |
Family
ID=61902455
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/715,037 Active 2028-01-08 US10888515B2 (en) | 2007-08-13 | 2017-09-25 | Producing a topical solution composition |
US16/997,121 Active 2027-10-30 US11654099B2 (en) | 2007-08-13 | 2020-08-19 | Producing a topical solution composition |
US18/305,935 Pending US20230372229A1 (en) | 2007-08-13 | 2023-04-24 | Producing a topical solution composition |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/715,037 Active 2028-01-08 US10888515B2 (en) | 2007-08-13 | 2017-09-25 | Producing a topical solution composition |
US16/997,121 Active 2027-10-30 US11654099B2 (en) | 2007-08-13 | 2020-08-19 | Producing a topical solution composition |
Country Status (1)
Country | Link |
---|---|
US (3) | US10888515B2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10888515B2 (en) * | 2007-08-13 | 2021-01-12 | Shantel Medical Supply Corp. | Producing a topical solution composition |
JP6997222B2 (en) | 2017-06-23 | 2022-01-17 | ザ プロクター アンド ギャンブル カンパニー | Compositions and Methods for Improving the Appearance of the Skin |
CA3102288A1 (en) | 2018-07-03 | 2020-01-09 | The Procter & Gamble Company | Method of treating a skin condition |
CN109481377A (en) * | 2018-11-28 | 2019-03-19 | 黄犟兵 | A kind of skin barrier remediation composition and preparation method thereof |
US10959933B1 (en) | 2020-06-01 | 2021-03-30 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
JP2023528616A (en) | 2020-06-01 | 2023-07-05 | ザ プロクター アンド ギャンブル カンパニー | Method for improving skin penetration of vitamin B3 compounds |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6270780B1 (en) * | 1997-07-25 | 2001-08-07 | Chesebrough-Pond's Usa Co., Division Of Conopco | Cosmetic compositions containing resveratrol |
US10888515B2 (en) * | 2007-08-13 | 2021-01-12 | Shantel Medical Supply Corp. | Producing a topical solution composition |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6238678B1 (en) | 1995-11-06 | 2001-05-29 | The Procter & Gamble Company | Methods of regulating skin appearance with vitamin B3 compound |
FR2764189B1 (en) * | 1997-06-09 | 1999-08-27 | Coletica | USE OF SULPHITES AND METABISULPHITES FOR THE MANUFACTURE OF COSMETIC OR PHARMACEUTICAL COMPOSITIONS, ESPECIALLY IN DERMATOLOGY, WITH A MELANOGENESIS INHIBITOR EFFECT OR WITH DEPIGMENTING ACTIVITY |
DE19737737C2 (en) | 1997-08-29 | 1999-09-23 | Henkel Kgaa | Use of dialkyl carbonates |
FR2777183B1 (en) | 1998-04-10 | 2001-03-02 | Oreal | USE OF AT LEAST ONE HYDROXYSTILBENE IN A COMPOSITION FOR PROMOTING DEQUAMATION OF THE SKIN AND COMPOSITION COMPRISING SAME |
WO2004103265A2 (en) | 2003-05-26 | 2004-12-02 | Enprani Co., Ltd. | Whitening and antioxidative cosmetic composition containing resveratrol and method for preparing the same |
FR2856074B1 (en) * | 2003-06-12 | 2007-05-25 | Lallemand Sa | ALCOHOL TOLERANT MALOLACTIC STRAINS FOR MATURING MEDIUM OR HIGH PH WINES |
US20060078530A1 (en) | 2004-10-12 | 2006-04-13 | Liu Kay M | Using high-density grapes to rejuvenate human skin |
US20070003644A1 (en) | 2005-04-16 | 2007-01-04 | Unitel Technologies, Inc. | Concentrated polyphenolic product and process for making the same |
US20070122502A1 (en) * | 2005-11-30 | 2007-05-31 | Logsdon Lawrence M | Therapeutic juice composition for women |
US9770480B2 (en) | 2007-08-13 | 2017-09-26 | Shantel Medical Supply Corp. | Producing a topical solution coposition |
-
2017
- 2017-09-25 US US15/715,037 patent/US10888515B2/en active Active
-
2020
- 2020-08-19 US US16/997,121 patent/US11654099B2/en active Active
-
2023
- 2023-04-24 US US18/305,935 patent/US20230372229A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6270780B1 (en) * | 1997-07-25 | 2001-08-07 | Chesebrough-Pond's Usa Co., Division Of Conopco | Cosmetic compositions containing resveratrol |
US10888515B2 (en) * | 2007-08-13 | 2021-01-12 | Shantel Medical Supply Corp. | Producing a topical solution composition |
US11654099B2 (en) * | 2007-08-13 | 2023-05-23 | Shantel Medical Supply Corp. | Producing a topical solution composition |
Non-Patent Citations (2)
Title |
---|
"Health Nutrition Benefit Facts Drinking Red White Wine Alcohol Calorie" (https://www.thewinecellarinsider.com/wine-topics/wine-educational-questions/health-nutrition-benefits-of-drinking-red-and-white-wine/#:~:text=Vitamins%20and%20minerals%20found%20in,are%20also%20found%20in%20wine) accessed 3/19/2024 * |
"What is the Acidity in Wine?" (https://www.wineenthusiast.com/basics/advanced-studies/what-is-acidity-in-wine/) accessed 3/13/2024 * |
Also Published As
Publication number | Publication date |
---|---|
US20210030662A1 (en) | 2021-02-04 |
US10888515B2 (en) | 2021-01-12 |
US20180104175A1 (en) | 2018-04-19 |
US11654099B2 (en) | 2023-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11654099B2 (en) | Producing a topical solution composition | |
US9770480B2 (en) | Producing a topical solution coposition | |
US8945523B2 (en) | Skin lightening composition for hyperpigmented skin | |
KR101809266B1 (en) | Cosmetic composition containing propolis complex extracts | |
WO2012172199A1 (en) | Composition based on camellia japonica and polygonum hydropiper for protecting the skin | |
KR101142541B1 (en) | Anti-wrinkle cosmetic composition containing oriental herb extract treated by enzyme and its extraction method | |
KR100953278B1 (en) | Cosmetic composition | |
KR101744889B1 (en) | Composition for Anti-oxidation, Whitening and Wrinkles protection | |
JP2001158728A (en) | Agent for promoting production of hyaluronic acid and skin preparation for external use | |
CN103494737A (en) | Cosmetic preparation using ginger flower as anti-ageing and skin-protecting factor and preparation method of cosmetic preparation | |
KR20100006796A (en) | Anti-aging cosmetic composition comprising herb ferment extract | |
JP3998085B2 (en) | Hyaluronic acid amount increase accelerator | |
CN107693411B (en) | Composition containing extract of sunflower sprout and semen Ciceris Arietini with antiinflammatory effect | |
KR102371360B1 (en) | Cosmetic composition having a whitening and moisturizing effect containing honey, schisandra fruit, Lycium chinese and green tea far-infrared mixed extract as active ingredients | |
KR101697340B1 (en) | Cosmetic composition containing ginseng berry extracts and polygonum multiflorum extracts | |
JP2013032331A (en) | Lipid production-inhibiting agent, sebum production-inhibiting agent, and triacylglycerol production-inhibiting agent | |
KR20160020038A (en) | Cosmetic Composition containing Frangipani Oil or Fermented Frangipani Oil | |
KR101701502B1 (en) | Composition having effects of skin moisturizing, exfoliating, improving skin elasticity, inhibiting erythema, anti-wrinkle or improving skin photoaging comprising decanal or salt thereof | |
KR101521239B1 (en) | Cosmetic composition for anti-aging containing the extract of fermentative Scutellaria baicalensis by Laetiporus Sulphureus | |
KR102419399B1 (en) | Cica-care cream composition and manufacturing method thereof | |
KR101545552B1 (en) | Cosmetic composition for whitening containing the extract of fermentative Scutellaria baicalensis by Laetiporus Sulphureus | |
KR102305942B1 (en) | Body cosmetics composition comprising vegetable extract and tumeric extract by multiple fermentation steps | |
KR20090011673A (en) | Skin external composition for treating pimple | |
KR101754556B1 (en) | Composition having effects of skin moisturizing or improving skin elasticity comprising suberic acid or salt thereof | |
JP4047230B2 (en) | Skin preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SHANTEL MEDICAL SUPPLY CORP., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LIU, KAY;REEL/FRAME:063797/0507 Effective date: 20120207 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |